Zymeworks Inc. Form 8-K Summary
Business Context and Reporting Period
Zymeworks Inc. filed a Form 8-K reporting a planned voluntary transfer of its common stock listing from the New York Stock Exchange (NYSE) to The Nasdaq Stock Market LLC (Nasdaq). The board authorized the action on November 30, 2022; the report was dated December 5, 2022.
Key Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating and financial metrics.
Material Changes
- The company notified the NYSE of its intention to withdraw its common stock listing from the NYSE.
- NYSE trading was expected to end at market close on or about December 15, 2022.
- Nasdaq trading was expected to begin at market open on or about December 16, 2022.
- The common stock was approved for Nasdaq listing and was expected to continue trading under the symbol ZYME.
- The reported security identifiers were CUSIP 98985Y 108 and ISIN US98985Y1082.
Outlook, Risks, and Unusual Items
The filing does not provide financial guidance or management commentary regarding operations. The principal disclosed event is the exchange listing transfer. The stated transition dates were expressed as approximate and should be confirmed through subsequent company or exchange disclosures.
Investor Verification Items
- Confirm the effective NYSE delisting and Nasdaq commencement dates.
- Verify that the common stock continued trading under the symbol ZYME on Nasdaq.
- Review subsequent filings for any operational, financing, or financial impacts associated with the listing transfer.
- Note that the Regulation FD disclosure and attached press release were furnished rather than filed for purposes of Section 18 liability, except where expressly incorporated by reference.